Cancer Drug Parity Act of 2017
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Cancer Drug Coverage Act of 2017
This bill amends the Public Health Service Act to require group and individual health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medication approved by the Food and Drug Administration that is prescribed based on a finding by the treating physician that the medication is medically necessary for cancer treatment and is clinically appropriate in terms of type, frequency, extent site, and duration.
To comply with this requirement, health plans may not, for anticancer medications: (1) change or replace benefits to increase out-of-pocket costs; (2) reclassify benefits to increase costs; or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.Referred to the Subcommittee on Health.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 1409: Cancer Drug Parity Act of 2017. 115th Congress. Open America. https://openamerica.io/bill/115-HR-1409/
"H.R. 1409: Cancer Drug Parity Act of 2017." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-1409/.
H.R. 1409, 115th Cong. (2026), https://openamerica.io/bill/115-HR-1409/.
[H.R. 1409: Cancer Drug Parity Act of 2017](https://openamerica.io/bill/115-HR-1409/)